Published in J Immunol on July 01, 2006
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol (2010) 4.79
Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov (2010) 4.47
Complement-targeted therapeutics. Nat Biotechnol (2007) 3.24
Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood (2008) 2.22
Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood (2011) 2.11
Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood (2011) 1.91
NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood (2007) 1.69
Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood (2008) 1.58
Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol (2008) 1.58
Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement. Leuk Lymphoma (2012) 1.54
Complement is activated by IgG hexamers assembled at the cell surface. Science (2014) 1.52
Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica (2009) 1.38
The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood (2010) 1.34
Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis (2011) 1.31
Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood (2008) 1.30
Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs (2012) 1.28
Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med (2008) 1.26
Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol (2012) 1.26
Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood (2011) 1.24
Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol (2012) 1.21
Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. J Immunol (2013) 1.18
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica (2014) 1.17
Mechanisms of action of CD20 antibodies. Am J Cancer Res (2012) 1.15
Building better monoclonal antibody-based therapeutics. Nat Rev Cancer (2015) 1.15
Medical applications of leukocyte surface molecules--the CD molecules. Mol Med (2007) 1.12
Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J Immunol (2012) 1.12
Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci U S A (2016) 1.09
B-cell targeted therapeutics in clinical development. Arthritis Res Ther (2013) 1.09
Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL). Cancer (2013) 1.07
Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. Cancer Immunol Res (2016) 1.05
Radioimmunotherapy of non-Hodgkin's lymphoma: from the 'magic bullets' to 'radioactive magic bullets'. Yale J Biol Med (2011) 1.04
An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy. Mol Ther (2010) 1.00
Ofatumumab. MAbs (2009) 0.98
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood (2015) 0.98
New antibody approaches to lymphoma therapy. J Hematol Oncol (2014) 0.97
Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia. Hematol Oncol Clin North Am (2009) 0.93
rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia. Clin Cancer Res (2011) 0.93
Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors. Leukemia (2013) 0.92
Chlamydia Pneumoniae CdsL Regulates CdsN ATPase Activity, and Disruption with a Peptide Mimetic Prevents Bacterial Invasion. Front Microbiol (2011) 0.91
Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia. J Immunol (2014) 0.90
Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4. Cancer Res (2011) 0.90
Investigational immunotherapeutics for B-cell malignancies. J Clin Oncol (2010) 0.88
Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs (2013) 0.88
The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica (2011) 0.88
7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland. MAbs (2012) 0.88
Therapeutic antibodies against cancer. Hematol Oncol Clin North Am (2012) 0.87
Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. Haematologica (2015) 0.87
Engineered protease-resistant antibodies with selectable cell-killing functions. J Biol Chem (2013) 0.86
Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodies. Curr Hematol Malig Rep (2013) 0.86
HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis. Haematologica (2010) 0.86
Management of chronic lymphocytic leukemia. Haematologica (2014) 0.85
Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells. Mol Cancer Ther (2012) 0.85
Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Invest New Drugs (2009) 0.84
Novel human antibody therapeutics: the age of the Umabs. Biotechnol J (2008) 0.84
Expression of MS4A and TMEM176 Genes in Human B Lymphocytes. Front Immunol (2013) 0.84
Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells. PeerJ (2013) 0.83
Complement factor H-derived short consensus repeat 18-20 enhanced complement-dependent cytotoxicity of ofatumumab on chronic lymphocytic leukemia cells. Haematologica (2013) 0.83
Ofatumumab and its role as immunotherapy in chronic lymphocytic leukemia. Haematologica (2015) 0.82
Immunotherapy treatments of warm autoimmune hemolytic anemia. Clin Dev Immunol (2013) 0.82
Current approaches to fine mapping of antigen-antibody interactions. Immunology (2014) 0.82
Immunotherapy for B-cell lymphoma: current status and prospective advances. Front Immunol (2012) 0.82
Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL. Leukemia (2014) 0.82
The role of Fc receptors in HIV prevention and therapy. Immunol Rev (2015) 0.81
A novel human anti-interleukin-1β neutralizing monoclonal antibody showing in vivo efficacy. MAbs (2014) 0.81
Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives. Clin Dev Immunol (2011) 0.81
Ofatumumab. Nat Rev Drug Discov (2010) 0.81
Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells. Oncoimmunology (2015) 0.81
Protein engineering to target complement evasion in cancer. FEBS Lett (2013) 0.80
A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin lymphoma. J Immunother (2013) 0.80
Surface levels of CD20 determine anti-CD20 antibodies mediated cell death in vitro. PLoS One (2014) 0.79
Phase I study of ofatumumab, a human anti-CD20 antibody, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Jpn J Clin Oncol (2013) 0.79
One target, different effects: a comparison of distinct therapeutic antibodies against the same targets. Exp Mol Med (2011) 0.79
Affinity is an important determinant of the anti-trypanosome activity of nanobodies. PLoS Negl Trop Dis (2012) 0.79
Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential. Leuk Lymphoma (2014) 0.79
Monoclonal antibodies as disease modifying therapy in multiple sclerosis. Curr Neurol Neurosci Rep (2013) 0.79
An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica. Ther Adv Neurol Disord (2016) 0.78
Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. Haematologica (2015) 0.78
Ofatumumab: a novel monoclonal anti-CD20 antibody. Pharmgenomics Pers Med (2010) 0.78
Removal of the tag from His-tagged ILYd4, a human CD59 inhibitor, significantly improves its physical properties and its activity. Curr Pharm Des (2012) 0.78
Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages. Clin Exp Immunol (2015) 0.78
Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics. Clin Cancer Res (2016) 0.78
Immunotherapy in Chronic Lymphocytic Leukaemia (CLL). Curr Hematol Malig Rep (2016) 0.77
Rituximab for the treatment of patients with chronic lymphocytic leukemia. Cancer Manag Res (2010) 0.77
De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivity. Cancer Sci (2013) 0.77
Prevention trumps treatment of antibody-mediated transplant rejection. J Clin Invest (2010) 0.77
Role of ofatumumab in treatment of chronic lymphocytic leukemia. J Blood Med (2011) 0.76
Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency. MAbs (2015) 0.76
Anti-CD20 single chain variable antibody fragment-apolipoprotein A-I chimera containing nanodisks promote targeted bioactive agent delivery to CD20-positive lymphomas. Biochem Cell Biol (2015) 0.76
7th cancer scientific forum of theCancéropôle Lyon Auvergne Rhône-Alpes: March 20-21, 2012, Lyon, France. MAbs (2012) 0.76
CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies. Invest New Drugs (2016) 0.76
Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells. MAbs (2016) 0.76
Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others. Cancer Med (2013) 0.76
Combating rituximab resistance by inducing ceramide/lysosome-involved cell death through initiation of CD20-TNFR1 co-localization. Oncoimmunology (2016) 0.75
Targeted therapies in rheumatoid arthritis: Focus on rituximab. Biologics (2007) 0.75
Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab. JCI Insight (2017) 0.75
Novel targeted treatment strategies for refractory chronic lymphocytic leukaemia. Ther Adv Hematol (2011) 0.75
Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation. Cancer Sci (2016) 0.75
Fc receptor but not complement binding is important in antibody protection against HIV. Nature (2007) 7.96
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med (2009) 5.87
Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol (2003) 5.59
Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science (2007) 4.52
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood (2004) 3.38
Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci U S A (2002) 3.08
Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol (2007) 2.99
Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog (2007) 2.64
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol (2010) 2.51
Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum (2005) 2.37
Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J Virol (2003) 2.34
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood (2010) 2.31
Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood (2008) 2.22
Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood (2011) 2.13
Contrasting IgG structures reveal extreme asymmetry and flexibility. J Mol Biol (2002) 2.10
Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. J Virol (2002) 2.06
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood (2003) 2.04
The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J Virol (2004) 2.02
Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res (2013) 1.95
Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood (2011) 1.91
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol (2009) 1.90
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood (2002) 1.87
CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses. Eur J Immunol (2008) 1.84
Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. J Virol (2003) 1.84
Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum (2002) 1.79
Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest (2009) 1.76
Crucial role of antibodies to pertactin in Bordetella pertussis immunity. J Infect Dis (2003) 1.73
Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol (2009) 1.71
Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity. Blood (2013) 1.58
Crosstalk between human IgG isotypes and murine effector cells. J Immunol (2012) 1.53
The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun (2005) 1.52
Complement is activated by IgG hexamers assembled at the cell surface. Science (2014) 1.52
Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses. Eur J Immunol (2002) 1.50
Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica (2010) 1.49
Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol (2008) 1.46
Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol (2011) 1.44
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci U S A (2013) 1.42
CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res (2003) 1.40
Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res (2006) 1.39
Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol (2004) 1.39
Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica (2009) 1.38
Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood (2008) 1.38
Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br J Haematol (2007) 1.38
Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest (2003) 1.37
In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res (2010) 1.37
Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood (2011) 1.34
Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength. J Immunol (2011) 1.34
Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res (2008) 1.30
Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med (2008) 1.26
Systemic inflammation modulates Fc receptor expression on microglia during chronic neurodegeneration. J Immunol (2011) 1.16
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs (2015) 1.16
Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. J Immunol (2011) 1.16